Publicação
Biovantage - a company focused on the new frontier of drug development via organ-on-a-chip technology: competitive landscape & business Model
| datacite.subject.fos | Ciências Sociais::Economia e Gestão | pt_PT |
| dc.contributor.advisor | Arantes-Oliveira, Nuno | |
| dc.contributor.author | Gordeev, Denise | |
| dc.date.accessioned | 2025-07-31T13:59:00Z | |
| dc.date.embargo | 2028-01-30 | |
| dc.date.issued | 2025-01-30 | |
| dc.date.submitted | 2024-12-17 | |
| dc.description.abstract | Within the "Building Companies Based on Science" field lab, this thesis focuses on creating BioVantage, a startup leveraging state-of-the-art organ-on-chip (OoC) technology to transform preclinical drug development. Anchored by a licensed neuromuscular junction-on-chip (NMJ OoC), BioVantage will initially specialize in neuromuscular diseases while exploring future applications for heart- and liver-OoC. By integrating artificial intelligence in combination with the OoC technology, our venture not only enhances the cost- and time-effectiveness and accuracy of drug discovery, but also significantly reduces the reliance on animal testing. In this report we detail a strategic business plan for BioVantage, positioning it as an ethical and innovative partner in advancing preclinical drug research while redefining industry standards. | pt_PT |
| dc.identifier.tid | 203959710 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10362/185808 | |
| dc.language.iso | eng | pt_PT |
| dc.relation | UID/ECO/00124/2013 | pt_PT |
| dc.subject | Amyotrophic lateral sclerosis | pt_PT |
| dc.subject | Animal testing | pt_PT |
| dc.subject | Artificial Intelligence | pt_PT |
| dc.subject | Contracted research organization | pt_PT |
| dc.subject | Lambert-Eaton Myasthenic Syndrome | pt_PT |
| dc.subject | Myasthenia gravis | pt_PT |
| dc.subject | Neuromuscular diseases | pt_PT |
| dc.subject | Organ-on-a-chip | pt_PT |
| dc.subject | Science-based entrepreneurship | pt_PT |
| dc.title | Biovantage - a company focused on the new frontier of drug development via organ-on-a-chip technology: competitive landscape & business Model | pt_PT |
| dc.type | master thesis | |
| dspace.entity.type | Publication | |
| rcaap.rights | embargoedAccess | pt_PT |
| rcaap.type | masterThesis | pt_PT |
| thesis.degree.name | A work project presented in partial fulfilment of the requirements for the Master’s degree in Management at Nova School of Business and Economics | pt_PT |